Core Insights - Annexon is focused on the classical complement pathway, targeting upstream aspects that drive inflammatory diseases across various tissues, including the brain and eye [2][3] - The company has three flagship programs, with Guillain-Barré syndrome being the most advanced, having completed a Phase III program and currently in discussions for global regulatory approval [3] - The second flagship program involves Tanruprubart in geographic atrophy, which is noted as the world's largest Phase III program for this condition, demonstrating significant preservation against disease progression [4]